La cadena de opciones muestra datos clave de las opciones de acciones de Roche Holding a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Roche Holding..

Roche Holding (OTC:RHHBY) Bolsa, Cadena de Opciones

Roche Holding

ROCHE HLDG LTD SPONS

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Novo Nordisk

Equities

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

RHHBY

Los aranceles de Trump podrían afectar a Novo Nordisk y otros gigantes farmacéuticos. Barclays advierte de impacto en márgenes y suministro.

Novo Nordisk, en la mira por los posibles aranceles farmacéuticos de Trump

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

REGN

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Cannabis

News

El cannabis medicinal reduce el uso de ansiolíticos: ¿Qué impacto tendrá en las grandes farmacéuticas?

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

Roche Holding AG

Legal

Press Releases

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis

Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis

Genentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

TD Cowen

Cowen & Co.

Comments

Roche Holding

Roche Holding (RHHBY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL